GuidelineClinical infectious diseases : an official publication of the Infectious Diseases Society of America2010
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.
Guideline in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 1,160 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cryptococcosis in Previously Healthy Adults
A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis
A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis
A Multi-center, Prospective, Randomized Trial of Amphotericin B in the Initial Antifungal Therapy for Non-HIV Cryptococcal Meningitis Patients
Who cites it
1,160 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,634 citations in OpenAlex.
- Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM.The Lancet. Infectious diseases · 2024Guideline
- Cryptococcal Meningitis: Comparison of Short- (≤ 1 Week) Versus Longer-duration (> 1 Week) Liposomal Amphotericin B Induction Therapy and Factors Associated With Clinical Outcomes in HIV and Non-HIV Patients.Open forum infectious diseases · 2026Trial
- Comparison of Bruker Biotyper Sirius, VITEK MS PRIME, and ASTA MicroIDSys MALDI-TOF MS Systems forAnnals of laboratory medicine · 2026Article
- Clinical Phenotypes, Immunosuppressive Exposures, and Outcomes in Pulmonary vs Extrapulmonary Cryptococcosis Among Non-HIV, Non-Transplant Adults: A U.S. Claims Analysis.Open forum infectious diseases · 2026Article
- A full review of online education resources available on antifungal stewardship.JAC-antimicrobial resistance · 2026Article
- Molecular types, clinical profile, and exploratory virulence-associated phenotypes of clinical Cryptococcus isolates from Amazonas, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Uncovering the impact of co-infections on disease severity and mortality in pulmonary cryptococcosis.BMC infectious diseases · 2026Article
- Use of Isavuconazole in the Treatment of Cryptococcosis: A Real-World Case Series.Infectious diseases and therapy · 2026Article
- Cryptococcal Infection Across Disease Stages: Host-Pathogen Interactions, Tissue Niches, and Translational Priorities.Pathogens (Basel, Switzerland) · 2026Review
- How have global guidelines advanced the management of cryptococcosis in two years?Expert review of anti-infective therapy · 2026Article
- Clinical and Economic Trade-Offs in Antifungal Therapy for Invasive Aspergillosis and Mucormycosis: A Markov Model-Based Analysis.Journal of fungi (Basel, Switzerland) · 2026Article
- Imaging evaluation and management of liver infections: a multimodality review.Abdominal radiology (New York) · 2026Review
- Asian consensus on diagnostic algorithm for invasive pulmonary fungal diseases in high-burden settings.Journal of translational internal medicine · 2026Article
- Protease-Mediated Dual Action Against Rice Blast: Suppression of Magnaporthe oryzae Ergosterol Biosynthesis Pathway and Enhancement of Rice Disease Resistance by Bacillus amyloliquefaciens SN16-1.Plant, cell & environment · 2026Article
- Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection.PLoS neglected tropical diseases · 2026Article
- An Organoselenium Compound Induces Death inACS omega · 2026Article
- Temporal shifts in adaptive immunity drive HIV-associated cryptococcal IRIS: mechanisms, models, and therapeutic opportunities.NeuroImmune pharmacology and therapeutics · 2026Article
- Clinical Characteristics and Predictors of One-Year Mortality in HIV and Non-HIV Patients with Cryptococcal Infections in a Middle-Income Setting: A Multicenter Cohort Study.Journal of fungi (Basel, Switzerland) · 2026Article
- Click Chemistry Approach to Derivatisation of Fluconazole.Molecules (Basel, Switzerland) · 2026Article
- The novel antifungal agent NPD2560 perturbs the Rho1-centered signaling network to induce a cell wall integrity response.Microbiology spectrum · 2026Article
1,100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 13 institutions in 5 countries.
Funding
Abstract
Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Society of America guidelines from 2000 and include new sections. There is a discussion of the management of cryptococcal meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus (HIV)-infected individuals, (2) organ transplant recipients, and (3) non-HIV-infected and nontransplant hosts. There are specific recommendations for other unique risk populations, such as children, pregnant women, persons in resource-limited environments, and those with Cryptococcus gattii infection. Recommendations for management also include other sites of infection, including strategies for pulmonary cryptococcosis. Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas. Three key management principles have been articulated: (1) induction therapy for meningoencephalitis using fungicidal regimens, such as a polyene and flucytosine, followed by suppressive regimens using fluconazole; (2) importance of early recognition and treatment of increased intracranial pressure and/or IRIS; and (3) the use of lipid formulations of amphotericin B regimens in patients with renal impairment. Cryptococcosis remains a challenging management issue, with little new drug development or recent definitive studies. However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.